Plerixafor Plus G-CSF Resulted In Similar Cost But More Predictable Days Of Apheresis Compared To Chemotherapy Plus G-CSF For Mobilization Of Autologous Hematopoietic Stem Cells
Paul Shaughnessy(CHRISTUS Transplant Institute), Peter A. McSweeney(Mesoblast (United States)), Maureen Hougham(CHRISTUS Transplant Institute), Sheryl Selvey(Massachusetts College of Pharmacy and Health Sciences), Janet E. Murphy(Harvard University), Jill MacPherson(CHRISTUS Transplant Institute), Miguel Islas‐Ohlmayer(CHRISTUS Transplant Institute), J. Matous, Michael B. Maris(Colorado Blood Cancer Institute), K. Winkler, Moisés da Silva(Massachusetts College of Pharmacy and Health Sciences), Michael Steinberg(Massachusetts College of Pharmacy and Health Sciences)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k